INTENSE-TBM General Assembly Meeting
The 9th INTENSE-TBM General Assembly Meeting has been hosted by the University of Geneva (co-Principal Investigator: Prof. Alexandra Calmy) on 6-8 June 2024. At a time that 535 participants out of 768 were being randomized in the clinical trial, the General Assembly brought together 25 face-to-face attendees, including 2 external experts, over 3 days.
The INTENSE-TBM study is evaluating a revised, more intensive treatment of patients with tuberculous meningitis, including those with HIV infections.
All the countries in which the trial is taking place were represented: Côte d’Ivoire, South Africa, Madagascar and Uganda. Partners from France and Spain were also present, allowing extensive discussion about the trial progress, the feedback from the last independent committee meeting, as well as about dissemination and administrative issues (budget, payments).
Regarding the current recruitment rate, it is expected to include the last participant before the end of the year 2025 and to perform the last follow-up visit around mid-2026. The first results should then be available during the year 2026. The project has recently been awarded a grant from Global Health EDCTP3 to complete activities that were affected by the COVID-19 pandemic.